UPDATE 1-Gilead beats revenue estimates as HIV drugs offset weak hep C demand
July 30, 2019 at 16:32 PM EDT
Gilead Sciences Inc beat analysts' estimates for quarterly revenue on Tuesday, driven by higher sales of its HIV treatments, and the drugmaker raised its 2019 sales forecast.
